Yesterday’s post outlined expert recommendations for proactive therapeutic drug monitoring (pTDM). Today’s post reviews a study (NV Casteele et al. Clin Gastroenterol Hepatol 2019; 17: 1814-21) which identifies optimal levels at earlier time points. The authors note that “higher infliximab (IFX) concentrations during induction therapy are correlated with long-term relapse-free and colectomy-free survival.”
The authors analyzed data from 484 patients with active ulcerative colitis (UC) from two double-blind, placebo-controlled, parallel group studies: ACT-1 and ACT-2.
- IFX levels ≥18.6 mcg/mL at week 2, ≥10.6 mcg/mL at week 6, and ≥34.9 mcg/mL at week 8 were associated with Mayo endoscopic scores (MES) of ≤1 at week 8.
- IFX level of ≥5.1 mcg/mL at week 14 was associated with MES of ≤1 at week 30
- IFX level of ≥6.7 mcg/mL at week 14 was associated with MES of 0 at week 30
My take: In pediatric patients receiving monotherapy with an anti-TNF agent, checking earlier levels (week 6, week 8, or week 10) may help avoid low troughs which are associated with a higher likelihood of treatment failure. This study provides guidance on target levels at earlier time points.
Related blog posts:
- Briefly Noted: Induction Infliximab Levels Infliximab level ≥18 mcg/mL at week 6 was strongly associated with clinical and biologic response as well as achieving an infliximab level ≥5 mcg/mL at week 14 (AUC 0.85).
- Is Standard Infliximab Dose Too Low in Pediatrics?
- Combination Therapy Study Points to Central Role of Adequate Drug Levels
- Can Therapeutic Drug Monitoring with Monotherapy Achieve Similar Results as Combination Therapy for IBD? | gutsandgrowth The authors utilized TDM at week 10. If the IFX level was <20 mcg/mL, the dose and frequency of infliximab were both adjusted. If the level was between 20 & 25, either the frequency was adjusted or no adjustment, and if the level was >25, then no adjustment in dosing was performed.
- Don’t be Fooled About Withdrawing Immunomodulator Cotherapy -Look Past the Headline
Disclaimer: These blog posts are for educational purposes only. Specific dosing of medications/diets (along with potential adverse effects) should be confirmed by prescribing physician/nutritionist. This content is not a substitute for medical advice, diagnosis or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a condition.
Pingback: #NASPGHAN19 Selected Abstracts (Part 2) | gutsandgrowth
Pingback: IBD Updates December 2019 | gutsandgrowth
Pingback: Expert Guidance on Inflammatory Bowel Disease (Part 2) | gutsandgrowth
Pingback: Expert Consensus: New Recommendations for Therapeutic Drug Monitoring | gutsandgrowth
Pingback: Improving Outcomes with Proactive Therapeutic Drug Monitoring + Swiss COVID1- Data | gutsandgrowth